Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

Steroids and Cross-Linking for Ulcer Treatment

Дата публикации: 27-08-2026 00:00:00

Importance: Adjunctive topical corticosteroids and/or corneal cross-linking (CXL) have the potential to improve outcomes in bacterial keratitis.
Objective: To determine the benefit of adjunctive topical difluprednate and CXL with riboflavin in addition to topical antibiotics.
Design, Setting, and Participants: This was a National Institutes of Health (NIH)-funded, sham, placebo-controlled trial randomizing participants to topical moxifloxacin, 0.5%, plus topical placebo plus sham CXL, vs topical moxifloxacin, 0.5%, plus difluprednate, 0.05%, plus sham CXL, vs topical moxifloxacin, 0.5%, plus difluprednate, 0.05%, plus CXL. Between September 2020 and October 2023, participants in clinics at the Aravind Eye Hospitals in India and Bascom Palmer Eye Institute, University of Miami, in Miami, Florida, were screened for inclusion. Included participants had smear- and/or culture-positive bacterial corneal ulcers with Snellen visual acuity of 20/40 or worse.
Main Outcomes and Measures:...

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Efficacy and Safety of Brolucizumab for Diabetic Macular Edema07.9701-12-2023
2Ndemex expands clinical toolbox for Demodex blepharitis010.9122-07-2026
3Sterile Intraocular Inflammation Associated With Faricimab09.1701-11-2024
4Four-zone scleral lens improves visual performance for irregular corneas0.5720-07-2026
5Postoperative Fungal Endophthalmitis and Trypan Blue Use in Cataract Surgery06.8301-07-2026
6New laser heat treatment could stop blindness before it starts08.6627-05-2026
7Subretinal Fluid After Repeated Low-Level Red Light Therapy09.9123-07-2026
8💯 VIZOX - ВОССТАНОВЛЕНИЕ ЗРЕНИЯ ДО «ЕДИНИЦЫ» БЕЗ ОПЕРАЦИИ ▶▶▶ ...08.4724-07-2026
9Detecting Glaucoma in Myopic Eyes With OCT0702-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 10.2. Источник: escholarship.org.